Sign in
CompletedPhase 1

Phase 1 Clinical Trial of CordSTEM-ST

Key facts

Who runs it
CHABiotech CO., Ltd
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
6 people enrolled
Started
30 Aug 2024
Ended
28 Apr 2025
Type of study
Interventional, 2 groups
Treatments tested
  • umbilical cord-derived mesenchymal stem cell
Record updated
19 November 2025

Who can take part

Age
25 years to 39 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Females aged ≥ 25 years and < 40 years
  • Individuals diagnosed with premature ovarian insufficiency: Individuals who have a follicle stimulating hormone (FSH) level of 40 IU/L or higher in the results of two tests conducted at least 4 weeks apart and are amenorrheic for at least 4 months
  • Individuals who voluntarily decide to participate and provide written consent

Who cannot take part

  • Individuals diagnosed with polycystic ovary syndrome
  • Individuals with any other conditions that may affect the result of this study
  • Individuals diagnosed with primary amenorrhea*; No secondary sex characteristics by age 13, Absence of menarche for 5 years after initial breast development, or Absence of menstruation by age 15

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical study will evaluate the safety and tolerability of CordSTEM-ST after administering a single dose in patients with premature ovarian insufficiency (POI), as well as identify the maximum tolerated dose (MTD) and evaluate the potential therapeutic effects.

The 2 groups in the trial

  • Study Group 1 (Low dose CordSTEM-ST)Treatment being tested

    Low dose CordSTEM-ST, 1 (single) administration

    Treatment: umbilical cord-derived mesenchymal stem cell

  • Study Group 2 (High dose CordSTEM-ST)Treatment being tested

    High dose CordSTM-ST, 1 (single) administration

    Treatment: umbilical cord-derived mesenchymal stem cell

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Single-dose, Phase 1 Clinical Trial to Evaluate the Safety, and Tolerability of Allogeneic Umbilical Cord-derived Mesenchymal Stem Cell Therapy in Patients With Premature Ovarian Insufficiency
Record updated
19 November 2025